Lu-177 PSMA Therapy Cost in India vs the US: Real Numbers and Your Financial Options

Medically reviewed by a nuclear medicine and theranostics specialist | Last reviewed: June 2026

This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - this is the PSMA track. If you are PSMA-positive and you have been researching Lu-177 PSMA therapy, one of the first things you want to know is what it actually costs and whether it is within reach. The short answer is that Lu-177 PSMA therapy cost in India is much lower than in the United States - often 60 to 85 percent less. This article gives you the real numbers, explains why that gap exists, and walks through your options if the US price is beyond your reach.

What Is Lu-177 PSMA Therapy?

Lutetium Lu-177 vipivotide tetraxetan - sold in the US under the brand name Pluvicto - is a radioligand therapy for men with mCRPC. It attaches to PSMA (prostate-specific membrane antigen), a protein found on most prostate cancer cells, and delivers targeted radiation directly to those cells. The US Food and Drug Administration approved Pluvicto in March 2022 for adults with PSMA-positive mCRPC who had already received androgen receptor pathway inhibitor (ARPI) therapy and taxane-based chemotherapy. In the Phase 3 VISION trial, the therapy was associated with a significant improvement in overall survival and radiographic progression-free survival compared with standard of care alone, with approximately a 38 percent reduction in the risk of death (hazard ratio 0.62). A standard course involves up to six infusion cycles, each spaced roughly six weeks apart.

What Does Pluvicto Cost in the United States?

The per-cycle drug cost in the US is approximately USD 27,000 per vial, based on a pharmacoeconomic analysis from NCBI Bookshelf, published by the Canadian Agency for Drugs and Technologies in Health. That same review estimated a mean of approximately 4.54 cycles per patient, placing total drug cost alone at roughly USD 122,489 per patient. On top of the drug itself, you also need to pay for a PSMA PET-CT scan before treatment starts (estimated at approximately USD 1,200 to 1,400 per scan in the same analysis), plus hospital fees for each infusion, oncologist visits, follow-up labs, and travel to a credentialed nuclear medicine center if one is not nearby. All told, a full course in the US typically costs USD 150,000 to 200,000 or more.

Medicare covers Pluvicto for eligible beneficiaries, and most major private insurers generally follow Medicare coverage rules - but prior authorization is required and denials occur. Cost, location, and insurance issues block treatment for many eligible patients, according to a real-world access analysis published on ASCO Daily News.

What Does Lu-177 PSMA Therapy Cost in India?

India produces lutetium-177 radiopharmaceuticals domestically through its Department of Atomic Energy network. That eliminates import markups that drive up costs in most other countries. A 2024 study published in The Lancet Regional Health - Southeast Asia, available through PubMed Central, reported that the radiopharmaceutical cost of 100 mCi of labelled Lu-177 PSMA at an Indian academic center was approximately 80,000 INR per cycle. With investigation costs and hospital admission fees included, the total per-cycle cost at that center came to approximately 125,000 INR - roughly USD 1,500 at 2024 exchange rates.

Private hospitals in India charge more than government academic centers but still cost far less than in the US. Across private-sector facilities, the per-cycle cost typically runs from approximately USD 4,000 to USD 8,500, depending on the hospital, city, and care needs. A full four-to-six cycle course at a private Indian hospital may range from approximately USD 20,000 to USD 50,000 all in - compared with USD 150,000 or more in the US. That is a potential saving of 60 to 85 percent.

India vs the US: Cost at a Glance

The figures below are based on published data and reported institutional pricing. They are approximate and will vary by hospital, patient complexity, and exchange rates. Always confirm current pricing directly with the facility you are considering.

Sources: NCBI Bookshelf CADTH pharmacoeconomic review (NBK594369); Lancet Regional Health Southeast Asia 2024 (PMC11415577). Exchange rate approximate at time of publication. Verify current institutional pricing directly before booking.

Why Is India So Much Cheaper?

Four factors drive the gap. First, domestic production of lutetium-177 through India's Bhabha Atomic Research Centre removes the import markups seen in the US and most of Europe. Second, hospital operating costs, staff wages, and real estate are substantially lower in India, and reduce patient costs. Third, government and academic hospitals in India charge at or near cost for the radiopharmaceutical itself. Fourth, a growing number of hospitals in Mumbai, Delhi, Chennai, Hyderabad, and Bengaluru now offer this therapy, which creates competitive pricing pressure in the private sector. Lower cost does not mean a different compound. The radioligand - lutetium-177 attached to a PSMA-targeting molecule - is the same therapy. What you pay less for is the delivery infrastructure, not the drug.

Confirm Eligibility Before You Travel or Plan Any Costs

Lu-177 PSMA therapy is not right for every man with mCRPC. Before you act on any cost comparison, you need to know whether you qualify. Core requirements include a confirmed PSMA-positive result on a PSMA PET scan, adequate kidney function and blood counts, and prior treatment with an ARPI and taxane chemotherapy. For a plain-language breakdown of those criteria, see our guide on whether you are a candidate for Lu-177 PSMA therapy. If you are not sure whether your blood work and imaging are in order, our article on the tests and scans needed before Lu-177 PSMA treatment explains what is typically required and what the results mean. Most Indian centers that treat international patients offer a remote teleconsult eligibility review - you send scan files and medical records, and a specialist reviews them before you book travel.

How to Negotiate Financial Barriers in the United States

If you are in the US and cost or coverage is the barrier, work through these steps before giving up.

• Get the prior authorization decision in writing. Ask your oncologist's team to submit a prior auth request. If denied, get the specific reason in writing - you need it to appeal.
• Appeal with a letter of medical necessity. Denials can often be reversed when your oncologist provides a detailed letter. Many nuclear medicine centers have financial navigation staff who handle these appeals regularly and know what language works with specific insurers.
• Ask about the manufacturer patient support program. Novartis, which makes Pluvicto, operates a patient assistance program. Ask your oncology team to contact it on your behalf. Eligibility typically depends on income and insurance status.
• Clarify your Medicare coverage. If you are on Medicare, ask your billing team specifically about Part B coverage for the drug and infusion, and confirm claims are filed under the correct codes.
• Look at clinical trials. Trials studying Lu-177 PSMA in different disease settings may provide access at no drug cost. Search clinicaltrials.gov for currently enrolling studies near you.
• Consider India if US barriers cannot be cleared. For patients who are uninsured, underinsured, or facing out-of-pocket costs that remain out of reach, India may be a realistic next step. See our guide on planning your Lu-177 PSMA treatment in India as an international patient for the full logistics.

Key Practical Points for Patients Traveling to India

• Confirm eligibility before you book. Send your PSMA PET scan images and report, recent blood work, and medical history to the center you are considering. Most major Indian centers offer remote review before you travel.
• Decide whether to stay in India between cycles. Cycles are spaced roughly six to eight weeks apart. Staying in India for the full course avoids repeated long-haul flights and often costs less overall. Returning home between cycles is also feasible but requires more planning.
• Follow radiation safety guidance after each cycle. After each infusion, you will need to keep distance from pregnant women and young children for a few days. Your team will advise when it is safe to fly - timing your return matters for airport radiation screening.
• Budget for the complete trip. Include flights, accommodation for yourself and a companion, local transport, and daily expenses. Even with all of this factored in, total costs for patients from the US, UK, or GCC countries typically remain well below what treatment would cost at home.
• Arrange remote follow-up for labs between cycles. Blood counts, kidney function, and PSA can often be done at a local lab at home and sent electronically to your Indian team. Ask about their remote monitoring protocol before you commit.

The Bigger Access Gap

The most acute access problem extends beyond the US-India price difference. In many countries - including most of sub-Saharan Africa, large parts of the Middle East outside major urban centers, most of Southeast Asia, and parts of South America - Lu-177 PSMA therapy is not commercially available at all. For patients in those regions, traveling to India is not a cost-comparison decision. It is often the only option that exists. If your insurer has denied coverage and you need to map out every financial alternative available to you, our article on what to do when insurance will not cover Lu-177 PSMA therapy covers those paths step by step.

What the Numbers Cannot Tell You

Cost comparisons only go so far. The more fundamental question is whether Lu-177 PSMA therapy is appropriate for you at this stage of your cancer. Not every man with mCRPC qualifies. Your PSMA PET result, kidney function, prior treatment history, and current performance status all need to be assessed first. If you are not sure whether you qualify - or if you have been told you do not qualify and want a second opinion - you can send your PSMA PET scan and recent records for a remote eligibility review before you travel anywhere. If Lu-177 PSMA turns out not to be suitable, a review of the alternatives available at your disease stage is part of that same conversation. Request a no-obligation eligibility review through HealthUnwired to get a specialist's view of your case before making any treatment or travel decisions.

When to Talk to Your Doctor

Bring up cost and access questions with your oncologist or nuclear medicine specialist if your prostate cancer has progressed on hormone therapy and chemotherapy and you want to know what comes next; if you are eligible but the US cost is out of reach; if you are in a country where the therapy is not available and you are considering traveling to access it; or if your insurer has denied prior authorization and you need to understand your appeal rights.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.